HESA-A对转移性结肠癌患者的抗癌作用。
Anticancer effects of HESA-A in patients with metastatic colon cancer.
作者信息
Ahmadi Amrollah, Mohagheghi Mohammadali, Karimi Mehrdad, Naseri Mohsen
机构信息
Institute of Cancer Research, Medical Sciences/University of Tehran, Tehran, Iran.
出版信息
Integr Cancer Ther. 2009 Mar;8(1):71-4. doi: 10.1177/1534735408327995. Epub 2009 Jan 15.
BACKGROUND
HESA-A is a natural biological compound of herbal-marine origin. The aim of this study was to investigate the therapeutic effects of HESA-A in patients with metastatic colon cancer.
METHODS
Fifty consecutive patients with end-stage colon cancer and liver metastasis at the Cancer Research Center of Tehran University of Medical Sciences were studied. Patients received HESA-A 50 mg/kg/d orally in 2 to 3 divided doses for 6 months. The patients were assessed at the start and end of the 1st, 2nd, 4th, 8th, 12th, 16th, 20th, and 26th weeks of the study. The Karnofsky Performance Scale questionnaire was completed for each patient.
RESULTS
The mean Karnofsky performance score increased from 33.6 +/- 9.8 to 63.3 +/- 11 after 10 weeks of study. No significant hepatic or hematological adverse effects were seen during the study.
CONCLUSION
It seems that HESA-A is an effective and safe anticancer drug, which can be used in selected patients.
背景
HESA - A是一种源自草药 - 海洋的天然生物化合物。本研究旨在探讨HESA - A对转移性结肠癌患者的治疗效果。
方法
对德黑兰医科大学癌症研究中心连续50例晚期结肠癌伴肝转移患者进行研究。患者口服HESA - A，剂量为50 mg/kg/天，分2至3次服用，共6个月。在研究的第1、2、4、8、12、16、20和26周开始及结束时对患者进行评估。为每位患者完成卡诺夫斯基性能量表问卷。
结果
研究10周后，卡诺夫斯基性能评分均值从33.6±9.8提高到63.3±11。研究期间未观察到明显的肝脏或血液学不良反应。
结论
HESA - A似乎是一种有效且安全的抗癌药物，可用于特定患者。
Zotero 插件